Endotronix Presents Positive PROACTIVE-HF Clinical Trial Results for its Cordella Pulmonary Artery Sensor

Endotronix, Inc. Illinois Pennsylvania

The trial met primary safety and efficacy endpoints, demonstrating a markedly low rate of heart failure hospitalizations for NYHA class III HF patients.The results support the company's pre-market approval (PMA) application for U.S. market access, which is under review with the U.S. Food and Drug Administration (FDA).View original content:https://www.prnewswire.co.uk/news-releases/endotronix-presents-positive-proactive-hf-clinical-trial-results-for-its-cordella-pulmonary-artery-sensor-302080677.html